Loading
JNJ-79635322 is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
JNJ-79635322 is an investigational agent whose form is not stated in the registry developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JNJ-79635322 will be administered as SC injection. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma) and NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma), in multiple myeloma. The largest, NCT07518186, plans to enrol 700 participants with primary completion expected 2029-04-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.JNJ-79635322 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JNJ-79635322" OR ABSTRACT:"JNJ-79635322") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JNJ-79635322, not a curated reading list.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.